Drug Delivery Business News

In this video, Sean Whooley, Associate Editor at?MassDevice?& head driver of?Drug Delivery Business News,?sits down with Kayleen Brown, Managing Editor at?DeviceTalks, to talk all things diabetes, in honor of?#NationalDiabetesMonth. During the interview, Sean discusses: - Lessons learned from covering news for DDBN - How Sean got into covering the?#DiabetesIndustry - His thoughts on interviewing key leaders in the diabetes space - What he enjoys most about covering the?#Diabetes?industry - The?#MedicalDevices/#DrugDevices?that are needed for those in the?#DiabetesCommunity - Some big stories he covered in 2024, such as; news from?Medtronic,?Abbott,?Dexcom,?Tandem Diabetes Care,?Beta Bionics, &?Insulet Corporation - His reflection on attending the?American Diabetes Association?Scientific Sessions in June - And much more! Kayleen also shares a personal story on her connection to the diabetes community. Watch the video below, & for the for the biggest?#DiabetesTech?stories of the year so far, & what diabetes tech companies have been up to this month, see the comment section below????? #PatientCare?#Healthcare?#DiabetesAwareness?#DiabetesCare?#InsulinDelivery?#InsulinPumps?#CGM?#BloodGlucose?#Insulin?#DiabetesWellBeing?#DiabetesMonth?#DiabetesLife?International Diabetes Federation

There's a new CEO at Dutch insulin pump developer ViCentra — maker of the Kaleido pump — and he brings significant experience in medtech leadership. That includes playing a pivotal role in launching the world’s first hybrid closed-loop insulin pump system at Medtronic. The appointment comes as ViCentra looks to accelerate growth and broaden access to Kaleido. Read more: https://lnkd.in/eD5EEUMY #medtech #medicaldevices #diabetes #insulin #insulinpump #automatedinsulindelivery #personnelmoves

Abbott's latest innovation in continuous glucose monitoring — the Lingo system — has now landed on the world's largest online retailer, as it's now available for purchase on Amazon. The company built Lingo on its FreeStyle Libre CGM technology platform. The consumer biowearable is available for consumers 18 years and older not on insulin. It tracks glucose in real time and provides personal insights and coaching. Abbott designed it to help people build healthy habits, retain their metabolism and improve their overall wellbeing. Read more: https://lnkd.in/exmcAAEE #medtech #medicaldevices #CGM #glucose #sensor #biosensor #wearable #retail #amazon #diabetes

More automated insulin delivery options are on the way for people with #type2diabetes. Tandem Diabetes Care announced today that the FDA cleared its Control-IQ+ automated insulin delivery algorithm for people with type 2 diabetes. Control IQ+ builds on the company’s proven Control-IQ algorithm and includes enhancements to accommodate input of expanded weight and total daily insulin ranges. “More than 2 million people in the U.S. rely on intensive insulin therapy to manage their type 2 diabetes, and we are proud to bring this life-changing technology to a group that has historically had limited options for diabetes management.” Read more at Drug Delivery Business News: https://lnkd.in/gbFwGFn9 #medtech #medicaldevices #insulin #diabetes #automatedinsulindelivery #insulinpumps #fda

A study published in the?Journal of Diabetes Science and Technology looked at the latest-generation Abbott?FreeStyle Libre 3, Dexcom?G7?and Medtronic?Simplera?CGMs against different comparator methods and during clinically relevant glycemic scenarios. Investigators hope comprehensive new study guidelines — if implemented in a future standard — can "help ensure the continued safety and reliability of CGM systems as an increasing number of manufacturers enter the market." Read more here: https://lnkd.in/eitsxMFV #diabetes #CGM #medtech #medicaldevices #clinicaltrials

“We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives." Insulet generated more than $2 billion in full-year revenue for the first time in the company's history in 2024. Read more about the company's fourth-quarter and full-year results here: https://lnkd.in/e_wdEpJV #medtech #medicaldevices #diabetes #earnings #insulin #insulinpumps #automatedinsulindelivery

Today's Medtronic third-quarter earnings report and call included some interesting details on the company's growing #Diabetes business unit. Among the topics were expanded indication for the MiniMed 780G, updates on the next-gen Simplera Sync sensor and more. Read all about it: https://lnkd.in/eDAr2ttK #medtech #medicaldevices #medicaldevice #insulin #insulinpump #automatedinsulindelivery #CGM #type2diabetes

Covering the medical device industry for 12 years, I've found that recalls involving infusion pumps can be some of the most serious. In fact, proper dosage is essential for any device that delivers medicine to people's bodies. #Porouspolymers play a critical role in the design of #drugdelivery devices. They are also unsung heroes for many other devices: #IVD tests, molecular diagnostic cartridges, #dialysis systems, ostomy bags, and more. Porex is an important supplier of porous polymer components. Tomorrow, Feb. 18, at 2 p.m. Eastern time, join me and top Porex experts — Asa Burke, the company's senior manager of product development, and Robert Kiblinger, product development engineer — to learn the information you need about porous polymer components in your medical devices. The webinar is free; you can stream it on demand as your schedule permits. Hope to see you there! (I'll include a registration link in the comments.) #manufacturing #medtech #meddevice

The Insulet Omnipod 5 automated insulin delivery (AID) system,?became the first and only such system cleared for patients with both type 1 and type 2 #diabetes last August. JAMA?today published outcomes from a study highlighting lowered HbA1c levels when using Omnipod 5 to manage type 2 diabetes. The study concluded that the lower HbA1c levels suggest AID could prove a beneficial and safe option for this patient population. Read more at Drug Delivery Business News: https://lnkd.in/enTJT9k3 #medtech #medicaldevices #type2diabetes #insulin #insulindelivery #automatedinsulindelivery #insulinpumps

“We believe DXCM is moving in the right direction after facing significant headwinds earlier in 2024, and as we look into 2025, we think there are several catalysts that could push numbers higher as the year progresses." Analysts say Dexcom ended 2024 on a "high note," with more to come in 2025. See the breakdown of the company's fourth-quarter results here: https://lnkd.in/eydx5Wmh #medtech #medicaldevices #CGM #diabetes